The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials.
 
Praful Ravi
Research Funding - Bayer (Inst); Lilly (Inst); Telix Pharmaceuticals (Inst)
 
Lucia Kwak
No Relationships to Disclose
 
Andrew Acosta
No Relationships to Disclose
 
Saahil Rastogi
No Relationships to Disclose
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics
 
David Johnson Einstein
Honoraria - OncLive
Consulting or Advisory Role - Nimbus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Foundation Medicine (Inst); MiNK Therapeutics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Sanofi (Inst)
 
Peter K. Chang
No Relationships to Disclose
 
Andrew Wagner
No Relationships to Disclose
 
Rana R. McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Adam S. Kibel
Honoraria - Blue Earth Diagnostics; Janssen; Merck; profound; Roche
Consulting or Advisory Role - Advantagene; Bristol-Myers Squibb; Candel Therapeutics; Cellvax
Research Funding - Pfizer
 
Mary-Ellen Taplin
Honoraria - Abbvie; Arcus Biosciences; Arvinas; AstraZeneca; Blue Earth Diagnostics; Clovis Oncology; Constellation Pharmaceuticals; Epizyme; Hengrui Therapeutics; Janssen-Ortho; Pfizer; Propella Therapeutics; Research to Practice; Roivant; Targeted Oncology; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Janssen-Ortho (Inst)
Travel, Accommodations, Expenses - Advanced Prostate Cancer Society